Newsletter

028300 - HLB Co., Ltd.

028300 Summary

Biopharma

Stock Price & Overview

₩31,650 -1,300 (-3.95%) Close · Sep 8, 2026 KST

KOSDAQ | ₩KRW | Close: ₩31,650 ≈ US$23 · Market cap ₩4.2tn (≈ $3.0bn)

Home › 028300 › Filings

Convertible bonds bought back before maturity

DART

HLB Co., Ltd.

Filed Sep 8, 2026 KST · Filing · receipt 20260908900429

kstock has not written this one up. The title above is a translation of the Korean form name; the filing itself is on DART, in Korean.

Read the original on DART ↗ Korean. DART is Korea's electronic disclosure system, run by the Financial Supervisory Service — the filing equivalent of EDGAR.

Korean form name: 전환사채(해외전환사채포함)발행후만기전사채취득

028300

Price: ₩31,650
Change: -3.95%
Market cap: ₩4.2tn
Prev. close: ₩32,950

028300 Summary Compare to Peers

028300 data on kstock

Financials: 11 fiscal years
Valuation: Daily P/E, P/S, P/B, P/CF
Earnings: Eight quarters
Dividends: Per-share history

Every figure is taken from HLB Co., Ltd.'s own DART filings and matched on IFRS account codes, so a line holds across years where the Korean wording changed.

kstock analysis on 028300

HLB: Rivoceranib Optionality Cannot Hide A ₩121.3bn Half-Year Loss

Sep 4, 1:46 PM

All 028300 analysis

More 028300 filings

028300 - HLB Co., Ltd.

Convertible bonds bought back before maturity

028300

028300 data on kstock

kstock analysis on 028300

HLB: Rivoceranib Optionality Cannot Hide A ₩121.3bn Half-Year Loss

More 028300 filings

5% Ownership Report — Short Form

Adjustment of the conversion price

5% Ownership Report — Large Holdings

Insider / Major Shareholder Holdings Report

Securities issuance result (voluntary)

Loss Incurred on Derivatives Trading